We are thrilled to welcome Jessica to the RAPT leadership team at this pivotal time for the company,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT. “With her deep expertise as both an ...

RAPT Therapeutics (RAPT) announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the ...

BOSTON -- Patients with focal segmental glomerulosclerosis (FSGS) achieved some degree of proteinuria remission more often ...

Panelists discuss how patients with immunoglobulin A (IgA) nephropathy typically present with microscopic or gross hematuria, often during upper respiratory infections, along with variable proteinuria ...

For Andrew Schukraft, the doctor's appointment was just a routine sports physical exam. After all, the 16-year-old was in seemingly good health. But when he went in for the exam, the now 26-year-old's ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

Vera Therapeutics, Inc. (NASDAQ:VERA) said on Wednesday that it had completed full enrollment (431 participants) in the ...

Spherix Global Insights has released the first edition of its new Patient Dynamix™: IgA Nephropathy (US) series, delivering a comprehensive look at ...

IgAN research, focusing on real-world patient experiences, reveals unmet needs in disease education, affordability, and care navigationEXTON, PA, April 08, 2025 (GLOBE NEWSWIRE) -- Spherix Global ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.